Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Past Issue Archives
Self-Assessment Questions
Review of
Clinical Signs
Clinical Review
Pediatric Rounds
Resident Grand Rounds
Article Archives
Case Reports
Clinical Practice
Pediatric Rounds
Resident Grand Rounds
Review of
Clinical Signs

Guide to Reading
Hospital Physician
Editorial Board
Information for Authors

Reprints, Permissions, & Copyright
Site Map
Self-Assessment Questions

Pulmonary Disease

Answer 3
  1. LMWH subcutaneously throughout pregnancy and for several months postpartum. Both unfractionated heparin and LMWH are safe and effective in treating thromboembolic disease in pregnancy. Neither crosses the placenta, and their efficacies in treating DVT and PE are essentially equivalent. However, LMWH has a lower incidence of bleeding complications, heparin-induced thrombocytopenia, and osteoporosis as compared with heparin.5 Osteoporosis is a serious complication of full-dose heparin during pregnancy, with fractures occurring in 2% of treated women.5 LMWH does not appear to accelerate bone density loss. Warfarin is teratogenic and should not be administered during pregnancy.

    5. Ginsberg JS, Bates SM. Management of venous thromboembolism during pregnancy. J Thromb Haemost 2003;1:1435-42.

Click here to return to the questions


Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2009, Turner White Communications
Updated 7/6/07 • kkj